RNS Number : 3016I
Diaceutics PLC
08 August 2019

Diaceutics PLC
("Diaceutics" or the "Company")

Appointment of Head of Global Data

Diaceutics PLC, (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces that it has appointed Derek Hosty as Head of Global Data with immediate effect. Derek will lead Diaceutics' data team as it helps more patients across the world access precision medicine drugs by driving better diagnostic testing through unique data insights.

Diaceutics analyses significant volumes of data from worldwide clinical laboratories conducting diagnostic tests that determine which patients are eligible for specific precision medicine drugs. The resulting insights are presented to pharmaceutical companies, who then use the information to reach more patients.

Bringing almost 20 years of experience in software, analytics and product development to the role, Derek will be responsible for spearheading the Company's data strategy and the software tools to support it, with an aim to give more patients the best possible outcome. In doing so, Derek will drive further use of machine learning and AI solutions that predict gaps in diagnostic care. He will also lead the global data team in providing accurate, secure and prompt insights that will result in better precision medicine decisions.

Prior to this new role in Diaceutics, Derek was General Manager for Cloud and Data at Irish software provider Openet, with a focus on addressing specific business problems with analytics and machine learning. He was also Director of Technology Strategy for Data and Analytics at Norwegian telecommunications provider, Telenor Group, with a principal focus on contextual marketing, data privacy and security.

Ryan Keeling, Chief Innovation Officer, Diaceutics, said: "*We are leveraging the power of data to help break the industry mould so that more people get access to potentially life-saving new drugs. Our global data lake is expanding all the time and we are constantly innovating to ensure we are using and analysing that data in the most transformative way.*

"Derek has a long track record of leading data & analytics initiatives to achieve specific business goals. His broad knowledge of software and machine learning will be crucial to ensuring we consistently deliver game-changing insights that transform patient healthcare."

Derek Hosty, Head of Global Data, Diaceutics, said: *"Precision medicine is one of the most exciting developments in healthcare to date. However, it's not as effective as it should be because of low testing rates, slow test turnaround times and inconsistent results. Diaceutics realised early on that data can effect change and I look forward to using my experience to help Diaceutics achieve its mission to deliver seamless patient testing globally."*

Enquiries:

Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive Officer *via Walbrook PR*
Philip White, Chief Financial Officer

Cenkos Securities plc (Nominated adviser and broker) +44 (0) 20 3861 6630
Callum Davidson / Giles Balleny
Michael Johnson (Sales)

Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893

About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUGUPARUPBGCM